This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management

RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management

Format

Clinical Review

Time to Complete

45 minutes

Released

October 8, 2019

Expires

October 8, 2020
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

This CME-certified enduring activity is jointly provided by Rutgers Biomedical and Health Sciences and RedMedEd.

Commercial Supporter

Support for this activity has been provided through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

Severe, treatment-resistant asthma continues to be an extreme clinical challenge. An estimated 3%–10% of asthma patients have severe asthma, which is characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes.

Fortunately, there have been important developments regarding the clinical management of patients with severe asthma. The discovery that severe asthma comprises multiple phenotypes and distinct endotypes linked to differences in airway remodeling and inflammatory pathophysiology has potentially significant implications for managing this patient population. Also, several new tailored biologic therapies have been approved by the US Food and Drug Administration for use in patients with treatment-resistant severe asthma driven by eosinophilic inflammation, with other new treatments in late-stage development. In 2019, the Global Initiative for Asthma (GINA) updated its stepwise treatment guidelines; these guidelines address the use of biologic therapy for patients with severe asthma.

In this edition of RME Hot Seat, the members of our expert faculty answer challenging clinical questions on existing and emerging personalized treatment, strategies for implementing the most recent clinical guidelines when choosing optimal treatments for patients with severe asthma, the use of biomarkers to guide diagnosis and therapy, differentiating between severe asthma and poorly controlled asthma, and more.

Intended Audience

This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, and primary care providers (including nurse practitioners and physician assistants) involved in the care of patients with severe asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to discuss the most recent clinical guidelines for severe asthma treatment.

Peer Review

To help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by Sugeet Jagpal, MD, Assistant Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

This activity was pilot-tested for time required for participation by Ibrahim El Husseini, MD, and Renuka Rajagopal, MD.

Conflict Of Interest Disclosure Policy

According to the disclosure policy of Rutgers Biomedical and Health Sciences and to conform with Joint Accreditation requirements and FDA guidelines, individuals who are in a position to control the content of this educational activity are required to disclose to activity participants the existence of any relevant relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exception of nonprofit or government organizations and non–health care related companies, within the past 12 months. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Faculty

Michael E. Wechsler, MD, MMSc—Program Chair
Professor of Medicine
Director, Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

Dr. Wechsler has disclosed the following relevant financial relationships:
Grant/Research Support: AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA
Consultant: AstraZeneca, Equillium, Gala Therapeutics, Genentech, Genzyme, GlaxoSmithKline, Novartis Pharmaceuticals, Pulmatrix, Regeneron Pharmaceuticals, resTORbio, Sanofi, Sentien Biotechnologies, Teva Pharmaceuticals USA

Bradley E. Chipps, MD
Medical Director
Capital Allergy & Respiratory Disease Center
Sacramento, California

Dr. Chipps has disclosed the following relevant financial relationships:
Consultant, Speakers Bureau and Scientific Advisory Board: AstraZeneca, Circassia Pharmaceuticals, Genentech, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA

Flavia C. Hoyte, MD
Associate Professor of Medicine
Allergy/Immunology Fellowship Training Program
Division of Allergy/Immunology
National Jewish Health
University of Colorado
Denver, Colorado

Dr. Hoyte has disclosed the following relevant financial relationships:
Grant/Research Support: AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals, Teva Pharmaceuticals USA

Accredited Provider Disclosures

Reviewer
Sugeet Jagpal, MD, has disclosed no relevant financial relationships.

Field Testers
Ibrahim El Husseini, MD, and Renuka Rajagopal, MD, have disclosed no relevant financial relationships.

Rutgers Biomedical and Health Sciences Center for Continuing and Outreach Education
Patrick Dwyer, Director, CME, has disclosed no relevant financial relationships.

RedMedEd
Denise LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Yvette Murley, PhD, Medical Director, has disclosed no relevant financial relationships.
Heather Rafa, Program Manager, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation Statement

Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabled Use

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Dr. Wechsler discusses the investigational use of nonapproved products, including CRTH2 antagonists, anti-TSLP, and anti-IL33. Rutgers Biomedical and Health Sciences and RedMedEd do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any manufacturer of pharmaceuticals or devices, Rutgers Biomedical and Health Sciences or RedMedEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

Clicking "START ACTIVITY" will send you away from myCME to our partner site, RedMedEd, to complete the activity.

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately and will not be stored in your myCME CME History.

For questions regarding CME credit, please contact Rutgers Biomedical and Health Sciences at 973-972-4267 or ccoe@rbhs.rutgers.edu.

For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.

Privacy Policy

The hosting website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by Rutgers Biomedical and Health Sciences. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Rutgers Biomedical and Health Sciences so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Rutgers Biomedical and Health Sciences may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Rutgers Biomedical and Health Sciences. To review Rutgers Biomedical and Health Sciences’ CE privacy policy, click here http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html.

myCME privacy policy

Copyright

© 2019. This CME-certified program is held as copyrighted by Rutgers Biomedical and Health Sciences. Through this notice, Rutgers Biomedical and Health Sciences and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.
Add to Queue